Track Rani Therapeutics Holdings Inc. Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rani Therapeutics Holdings Inc. Class A Common Stock RANI · Stock Open Rani Therapeutics Holdings Inc. Class A Common Stock in new tab

0.5263 USD
EPS
-0.07
P/B
1.56
ROE
-172.15
Beta
0.68
Target Price
7.20 USD
Loading chart...
Key Metrics
Earnings dateMarch 31, 2027
EPS-0.07
Book Value0.34
Price to Book1.56
Debt/Equity7.40
% Insiders4.915%
Growth
Revenue Growth8.93%
Estimates
Forward P/E-2.77
Forward EPS-0.19
Target Mean Price7.20

DCF valuation

Model fair value for Rani Therapeutics Holdings Inc. Class A Common Stock (RANI)
Result
Sign in to run the valuation for RANI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 7.20 USD (low 5.00, high 11.00) · as of 14 Nov 2026
Low 5.00
Mean 7.20
High 11.00
Price 0.5263
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Rani Therapeutics Holdings Inc. Class A Common Stock Logo Rani Therapeutics Holdings Inc. Class A Common Stock Analysis (RANI)

United States Health Care Official Website Stock

Is Rani Therapeutics Holdings Inc. Class A Common Stock a good investment? Rani Therapeutics Holdings Inc. Class A Common Stock (RANI) is currently trading at 0.5263 USD. Market analysts have a consensus price target of 7.20 USD. This suggests a potential upside from current levels.

Earnings Schedule: Rani Therapeutics Holdings Inc. Class A Common Stock is expected to release its next earnings report on March 31, 2027. The market consensus estimate for Forward EPS is -0.19.

Investor FAQ

Does Rani Therapeutics Holdings Inc. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rani Therapeutics Holdings Inc. Class A Common Stock?

Rani Therapeutics Holdings Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 31, 2027. The company currently has a trailing EPS of -0.07.

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Exchange Ticker
NMS (United States) RANI
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion